Cargando…

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Yusuke, Yoshimura, Katsuhiro, Mori, Kazutaka, Kurabe, Nobuya, Kahyo, Tomoaki, Mori, Hiroki, Kawase, Akikazu, Tanahashi, Masayuki, Ogawa, Hiroshi, Inui, Naoki, Funai, Kazuhito, Shinmura, Kazuya, Niwa, Hiroshi, Suda, Takafumi, Sugimura, Haruhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078001/ https://www.ncbi.nlm.nih.gov/pubmed/27050074 http://dx.doi.org/10.18632/oncotarget.8528

Ejemplares similares

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
por: Inoue, Yusuke, et al.
Publicado: (2017)

Characterization of V‐set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells
por: Inoue, Yusuke, et al.
Publicado: (2017)

CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer
por: Yoshimura, Katsuhiro, et al.
Publicado: (2020)

YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer
por: Tsuchiya, Kazuo, et al.
Publicado: (2021)

m(6)A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer
por: Tsuchiya, Kazuo, et al.
Publicado: (2022)

SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers
por: Matsuura, Shun, et al.
Publicado: (2013)

Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation
por: Nakamura, Satoki, et al.
Publicado: (2015)

POLQ Overexpression Is Associated with an Increased Somatic Mutation Load and PLK4 Overexpression in Lung Adenocarcinoma
por: Shinmura, Kazuya, et al.
Publicado: (2019)

Insertionally polymorphic sites of human endogenous retrovirus-K (HML-2) with long target site duplications
por: Kahyo, Tomoaki, et al.
Publicado: (2017)

Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study
por: Takanashi, Yusuke, et al.
Publicado: (2020)

CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
por: Shinmura, Kazuya, et al.
Publicado: (2014)

Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study
por: Takanashi, Yusuke, et al.
Publicado: (2021)

High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer
por: Hu, De, et al.
Publicado: (2023)

Lipid biomarkers that reflect postoperative recurrence risk in lung cancer patients who smoke: a case–control study
por: Takanashi, Yusuke, et al.
Publicado: (2023)

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020)

Lung adenocarcinoma and squamous cell carcinoma difficult for immunohistochemical diagnosis can be distinguished by lipid profile
por: Yamashita, Takashi, et al.
Publicado: (2023)

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
por: Kahyo, Tomoaki, et al.
Publicado: (2018)

PD‐L1 and PD‐L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma
por: Okadome, Kazuo, et al.
Publicado: (2021)

8th Edition Tumor, Node, and Metastasis T-Stage Prognosis Discrepancies: Solid Component Diameter Predicts Prognosis Better than Invasive Component Diameter
por: Funai, Kazuhito, et al.
Publicado: (2020)

Improved complete portal 4-port robotic lobectomy for lung cancer: Hamamatsu Method KAI
por: Funai, Kazuhito, et al.
Publicado: (2023)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Thyroid transcription factor-1 expression in rectal adenocarcinoma metastatic to the lung
por: Takanashi, Yusuke, et al.
Publicado: (2023)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
por: Hirose, Takayuki, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Fluorescence navigation with indocyanine green for identification of intersegmental planes using a photodynamic eye camera
por: Funai, Kazuhito, et al.
Publicado: (2020)

Placement of KANI® plate inside the chest wall for rib fixation: Prevention for organ injuries caused by crossed rib edges and plate claws
por: Uebayashi, Asuka, et al.
Publicado: (2022)

Lung cancer development in patients with connective tissue disease–related interstitial lung disease: A retrospective observational study
por: Enomoto, Yasunori, et al.
Publicado: (2016)

BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma
por: Shinmura, Kazuya, et al.
Publicado: (2015)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b41rcvuil19pf95m5vi5l5rblq